FDA: Benefits Of Children Receiving Pfizer BioNTech Vaccine Outweigh Risks

Paediatric dose is one third of an adult's dose

The benefits of offering the Pfizer-BioNTech vaccine to children outweigh the risks, according to regulators in the United States.

Data from the company's own clinical trials found a paediatric dose - which is one third of an adult's dose - was safe and 90% effective.

Advisory boards to both the Food and Drug Administration and Centre for Disease Control made the recommendation last night.

The full membership of both organisations are to examine the decision, but are expected to follow the recommendation from the vaccine panel.

WATCH LIVE: The VRBPAC meeting is underway. Today’s topic is a request to amend Pfizer-BioNTech’s EUA for administration of their COVID-19 mRNA vaccine to children 5-11 years of age. https://t.co/7bjW57ETtM

— U.S. FDA (@US_FDA) October 26, 2021

FDA committee votes in favor of granting emergency use authorization for Pfizer's Covid-19 vaccine in children ages 5 to 11 https://t.co/uFL59ihtsD

— CNN Breaking News (@cnnbrk) October 26, 2021